Boston Scientific Corporation (NYSE: BSX), a leading global medical device company, boasts a market capitalization of approximately $96.41 billion. This innovative firm develops and sells a wide range of advanced medical technologies. The company operates in a highly competitive medical device industry alongside peers such as Medtronic plc (NYSE: MDT) and Stryker Corporation (NYSE: SYK), both of whom experienced comparatively smaller gains on the day.
On April 22, 2026, David Roman, an analyst at Goldman Sachs (NYSE: GS), adjusted the price target for Boston Scientific. The target was lowered to $84.00 from a previous $87.00. With the stock trading at $64.87 at the time, this new target still represents a significant potential upside of approximately 29.49% for investors, indicating continued confidence in its stock performance.
Despite the target reduction, Boston Scientific stock experienced a significant daily gain of 8.99%, closing at $64.87. This impressive rally follows a robust first-quarter earnings report that comfortably beat analyst estimates, showcasing strong financial results. Sales rose by 9%, and adjusted earnings per share (EPS) increased by 6% to $0.80, as highlighted by The Motley Fool.
The stock's rally occurred even as Boston Scientific lowered its full-year guidance. As reported by Reuters, the company reduced its 2026 sales growth forecast from a range of 10.5%-11.5% to a new range of 7%-8.5%. Despite this adjustment in corporate guidance, the company now expects adjusted earnings of $3.34 to $3.41 per share, reflecting its updated outlook on future market trends.
Interestingly, some analysts viewed this guidance cut positively. Leerink Partners analyst Mike Kratky called it a "major reset" that helps the stock, as highlighted by Investor's Business Daily. This perspective contributed to high investor interest, with trading volume reaching over 40.38 million shares, significantly above its 17 million average, demonstrating strong investor sentiment.
